1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

## UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA SANDRA L. KINNEY, et al., No. C-12-4477 EMC Plaintiffs, RELATED TO v. No. C-12-4478 EMC No. C-12-4615 EMC BRISTOL-MYERS SQUIBB COMPANY, et No. C-12-4616 EMC No. C-12-4617 EMC No. C-12-4619 EMC Defendants. No. C-12-4633 EMC No. C-12-4641 EMC No. C-12-4642 EMC No. C-12-4803 EMC AND ALL RELATED ACTIONS.

As the parties have informed the Court, the Judicial Panel on Multidistrict Litigation ("MDL") recently denied without prejudice transfer of the above-referenced cases. The Court thus has pending before it Plaintiffs' motions to remand.

ORDER RE SUPPLEMENTAL

**BRIEFING** 

The Court directs the Plaintiffs to file supplemental briefing. Defendants have taken the position that a distributor cannot issue additional warnings beyond those contained in the FDAapproved labeling or, under federal law, they will be subject to civil and/or criminal penalties for misbranding, In their supplemental brief, Plaintiffs should address why a distributor would not be liable for misbranding under federal law if it were to issue such additional warnings beyond those contained in the FDA-approved labeling. The Court notes that it previously asked for supplemental briefing on this very issue in the Caouette case, see Caouette v. Bristol-Myers Squibb Co., No. C-12

| 1814 EMC (Docket No. 41) (Order at 2) (asking "what should McKesson have done in the instant                   |
|----------------------------------------------------------------------------------------------------------------|
| cases to satisfy [the] duty [to warn]" and "how are those actions not inconsistent with or prohibited          |
| by federal law"); however, the Caouette Plaintiffs did not directly respond, focusing instead on the           |
| argument that Mensing applies only in the generic drug context. See id. (Docket No. 44) (Pls.'                 |
| Supp. Br. at 8). Plaintiffs in the cases at bar have similarly argued that <i>Mensing</i> is restricted to the |
| generic drug context. See, e.g., Kinney v. Bristol-Myers Squibb Co., No. 12-4477 EMC (Docket No.               |
| 18) (Reply at 10). Plaintiffs have yet to address the question (assuming the logic of <i>Mensing</i> 's        |
| impossibility analysis applies here) why it is not impossible for a distributor to provide additional          |
| warnings (as Plaintiffs contend is required by California law) and not contravene federal law.                 |

Although Plaintiffs are represented by different counsel, the Court shall require Plaintiffs to coordinate and file a single supplemental brief. The supplemental brief shall be filed by February 26, 2013.

IT IS SO ORDERED.

Dated: February 19, 2013

United States District Judge